NCT06023199 is a Phase 2 clinical trial of Voxelotor in Sickle Cell Disease, sponsored by Inova Health Care Services.

Who is sponsoring NCT06023199?

NCT06023199 is sponsored by Inova Health Care Services.

What drugs are being tested in NCT06023199?

Interventions in NCT06023199: Voxelotor.

What condition does NCT06023199 study?

NCT06023199 studies Sickle Cell Disease.

Is NCT06023199 still recruiting?

NCT06023199 is currently active, enrolled. Last updated 2 February 2026.

Last reviewed 2026-02-02 · How we verify

NCT06023199

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Assessing Physical Function in Sickle Cell Patients Taking Voxelotor

Active, enrolled Phase 2 Last updated 2 February 2026

What this trial tests

Phase 2 trial testing Voxelotor in Sickle Cell Disease in 6 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

23 October 2023

Primary endpoint
17 September 2025

15 June 2026

Quick facts

Lead sponsor	Inova Health Care Services
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	23 October 2023
Primary completion	17 September 2025
Estimated completion	15 June 2026
Sites	1 location across United States

Drugs / interventions tested

Voxelotor (voxelotor) — full drug profile →

Conditions studied

Sickle Cell Disease — all drugs for Sickle Cell Disease →

Sponsor

Inova Health Care Services — full company profile →

Who can join

Adults 18 to 65, any sex, with Sickle Cell Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Voxelotor is a novel hemoglobin polymerization inhibitor which has been demonstrated to reduce hemolysis and improve hemoglobin levels. There have been numerous studies examining the clinical impact of voxelotor in sickle cell disease (SCD) patients, but there are few published reports on the effects of treatment on physical function in patients with SCD. The hypothesis to be tested is that anemic SCD patients will have improvements in performance after 6 months of voxelotor treatment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Current and Future Therapeutics for Treating Patients with Sickle Cell Disease.
Barak M, Hu C, Matthews A, Fortenberry YM. · · 2024 · cited 14× · PMID 38786070 · DOI 10.3390/cells13100848

Verify or expand the search:

Other trials of Voxelotor

Trials testing the same drug.

NCT05981365 — Voxelotor CYP and Transporter Cocktail Interaction Study · Phase 1 · completed
NCT05289570 — Voxelotor for Improving Oxygen Saturation in Adults · Phase 2 · terminated
NCT05018728 — The Effect of Voxelotor on Cerebral Hemodynamic Response in Children With Sickle Cell Anemia · Phase 2 · terminated
NCT04335721 — A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease · Phase 1, PHASE2 · terminated
NCT04400487 — Actigraphy Improvement With Voxelotor (ActIVe) Study · Phase 4 · completed

Other recruiting trials for Sickle Cell Disease

Currently open trials in the same condition.

NCT07369024 — Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults · Phase 2 · recruiting
NCT06016634 — Alendronate for Osteonecrosis in Adults With Sickle Cell Disease · Phase 2 · recruiting
NCT06260891 — Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial · Phase 2 · recruiting
NCT07222475 — Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease · NA · recruiting
NCT07224360 — Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) · Phase 2 · recruiting

Other Inova Health Care Services trials

Trials by the same sponsor.

NCT06564207 — Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Adults · Phase 2 · not yet recruiting
NCT07167199 — Absorbable Staples Versus Conventional Skin Closure in Women Undergoing Cesarean Delivery · NA · not yet recruiting
NCT07437339 — Volume Reduction for Open Fracture Irrigation · Phase 4 · recruiting
NCT07485322 — Burn Pit Exposure in Veterans: A Cancer Screening Pilot Study at the Inova Saville Cancer Screening & Prevention Center · NA · not yet recruiting
NCT07335224 — Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06023199 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Inova Health Care Services
Last refreshed: 2 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06023199.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing